Therapeutic effects of HESA-A in patients with end-stage metastatic cancers

Integrative Cancer Therapies

Volumn 9, Issue 1, 2010, Pages 32-35

  Ahmadi, Amrollah ^a   Mohagheghi, Mohammadali ^a   Karimi, Mehrdad ^b   Golestanha, Seyed Ali ^b   Naseri, Mohsen ^b   Faghihzadeh, Soghrat ^c   Habibi, Gholamreza ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHED UNIVERSITY   (Iran)

^c TARBIAT MODARES UNIVERSITY   (Iran)

^d Farzan Clinical Research Institute   (Iran)

Author keywords

Antioxidant; Cancer; HESA A; Side effects

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CREATININE; HESA A; UNCLASSIFIED DRUG; UREA; ANTIOXIDANT; HESA A PREPARATION; HESA-A PREPARATION; PLANT MEDICINAL PRODUCT;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; BILIARY DUCT ADENOCARCINOMA; BILIARY TRACT ADENOCARCINOMA; BREAST CANCER; CANCER PATIENT; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; EPIGASTRIC PAIN; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEIOMYOSARCOMA; LIVER CELL CARCINOMA; LIVER METASTASIS; MALE; METASTASIS; OVARY CANCER; PANCREAS ADENOCARCINOMA; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; STOMACH ADENOCARCINOMA; THERAPY EFFECT; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; DAILY LIFE ACTIVITY; LIVER TUMOR; MIDDLE AGED; MORTALITY; NEOPLASM; PATHOLOGY; SALVAGE THERAPY; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS; PLANT PREPARATIONS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 77953922685     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735409357934     Document Type: Article

References (24)

1. Mackenbach JP, Huisman M., Andersen O., et al. Inequalities in lung cancer mortality by the educational level in 10 European populations. Eur J Cancer. 2004 ; 40: 126-135.
2. Collier DA, Neidle S. Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthroquinones. J Med Chem. 1988 ; 31: 847-857.
3. Costello AJ A randomized, controlled chemoprevention trial of selenium in familial prostate cancer: rationale, recruitment, and design issues. Urology. 2001 ; 57: 182-184.
4. Burk RF Selenium, and antioxidant nutrient. Nutr Clin Care. 2002 ; 5: 75-77.
5. Wang GQ, Dawsey SM, Li JY, et al. Effects of vitamin/ mineral supplementation on the prevalence of histological dysplasia and early cancer of esophagus and stomach: results from the general population trial in Linxian, China. Cancer Epidemol Biomarkers Prev. 1994 ; 3: 161-166.
6. Melendez E. Titanium complex in cancer treatment. Crit Rev Oncol Hematol. 2002 ; 142: 309-315.
7. Fernandez-Banares F., Cabre E., Esteve M., et al. Serum selenium and risk of large colorectal adenomas in a geographical area with a low selenium status. Am J Gastroenterol. 2002 ; 97: 2103-2108.
8. Denkhaus SE, Salinkow K. Nickel essentiality, toxicity and carcinogenicity. Crit Rev Oncol Hematol. 2002 ; 42: 35-56.
9. Ji YJ, Xiao B., Wang ZH, Cui MZ, Lu YY The suppression effect of light rare earth elements on proliferation of two cancer cell lines. Biomed Environ Sci. 2000 ; 13: 287-292.
10. Evangelov AM Vanadium in cancer treatment. Crit Rev Oncol Hematol. 2002 ; 42: 249-256.
11. Hiraoka K., Komiya S., Hamada T., Zenmyo M., Inove A. Osteosarcoma cell apoptosis induced by selenium. J Orthp Res. 2001 ; 19: 809-814.
12. Ahmadi A., inventor. Method of preparation of an antitumor herbal drug [HESA-A]. Islamic Republic of Iran patent 27741. 2002.
13. Ahmadi A., Naderi G., Asgary S. Evaluation of hepatoprotective potential of HESA-A (a marine compound) pretreatment against thioacetamide-induced hepatic damage in rabbits. Drugs Exp Clin Res. 2005 ; 31: 1-6.
14. Ahmadi A., Sadeghi Aliabadi H. Cytotoxicity and antitumor properties of a marine compound, HESA-A, on cancer cells. Daru. 2003 ; 11: 82-87.
15. Zeng H., Combs GF Jr. Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J Nutr Biochem. 2008 ; 19: 1-7.
16. Caruso F., Rossi M. Antitumor titanium compounds. Mini Rev Med Chem. 2004 ; 4: 49-60.
17. Guo J., Deng W., Zhang L., Li C., Wu P., Mao P. Prediction of prostate cancer using hair trace element concentration and support vector machine method. Biol Trace Elem Res. 2007 ; 116: 257-272.
18. Hajhashemi V., Ghafghazi T., Balali M., et al. Toxicological studies on an anticancer drug (HESA-A) with marine origin. Med J Islam Acad Sci. 2001 ; 14: 145-149.
19. Ahmadi A., Mohgheghi MA, Sharif-Tabrizi A. Introducing the therapeutic effects of HESA-A on osteosarcoma included in rabbits. In: Proceedings of the First National Congress on Cancer Research, Orumiah, Iran; 2001 :5-8.
20. Sadeghi-Aliabadi H., Ahmadi A. Cytotoxicity and antitumor properties of a marine compound on cancer cell (HESA-A). Med J Islam Acad Sci. 2000 ; 13: 55-61.
21. Fazly Bazzaz BS HESA-A, its cytotoxicity and mutagenicity. J Oncol Pharm Pract. 2006 ; 12: 60.
22. Ahmadi A. Analysis of HESA: report of Atomic Energy Organization of Iran (AEOI), Research Division, Tehran, Islamic Republic of Iran, 2004.
23. Ahmadi A., Mohagheghi MA, Fazeli MS, et al. HESA-A: new treatment for breast cancer and choroidal metastasis. Med Sci Monit. 2005 ; 11: CR300 - CR303.
24. Ahmadi A., Mohagheghi M., Karimi M., Golestanha SA, Naseri M. Anticancer effects of HESA-A in patients with metastatic colon cancer. Integr Cancer Ther. 2009 ; 8: 71-74.